Navigation Links
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/18/2009

rMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. Arpida Interim Results for six Months to 30 June 2007
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
5. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
6. IsoTis Reports Interim Results of Vote for Integra Merger
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)...   Ceres, Inc . (Nasdaq: CERE ... financial results for the three months ended May 31, ... Ceres reported that the company and its customers ... season in Brazil, which concluded in June, despite dry ... areas for part of the growing season. Yields of ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Researchers at Rensselaer Polytechnic Institute have developed a ... that measure only billionths of a meter thick. ... works on nearly any surface including silicon wafers, ... manufacturing. Sang-Kee Eah, assistant professor in the ...
... The awards recognize outstanding journalism demonstrating the essential ... , , , ... June 16 The Foundation for Biomedical Research (FBR) today announces ... awards, named in honor of FBR,s late chairman Dr. Michael E. ...
... , June 16 Cellectis bioresearch, the specialist in genome ... edition of The Genome Customization Award, for academic research teams across the ... line or that of a model organism using one or more meganucleases ... , , ...
Cached Biology Technology:Researchers develop ultra-simple method for creating nanoscale gold coatings 22010 Michael E. DeBakey Journalism Awards Announced 2Cellectis bioresearch Establishes The Genome Customization Award (TGCA) 2Cellectis bioresearch Establishes The Genome Customization Award (TGCA) 3Cellectis bioresearch Establishes The Genome Customization Award (TGCA) 4
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... for Comprehensive Medical Science, Fujita Health University and ... with colleagues from 9 other institutions, have identified ... over 160 mutant mouse strains with a systematic ... mouse lacking the Schnurri-2 protein (Shn-2 KO) that ...
... their group when they are under threat from predators and ... are parallels between cooperatively breeding fish,s and humans, regulation of ... the journal Proceedings of the Royal Society B . ... ), a cichlid fish which is popular in home aquariums, ...
... of studying up close the symbiotic relationship between a mosquito-sized ... advanced the scientific understanding of biological diversity. Jeffrey ... or more organisms that can be parasitic or mutualistic ... and competition. The Proceedings of the Royal ...
Cached Biology News:Induction of mild inflammation leads to cognitive deficits related to schizophrenia 2Environmental factors determine whether immigrants are accepted by cooperatively breeding animals 2Pirate-like flies connect symbiosis to diversity 2
... MiniOpticon 2-color real-time PCR detection system holds 48 x ... of 48 LEDs independently excites fluorescence (470-500 nm) for ... emitted light (523-543 nm and 540-700 nm). This item ... Mini thermal cycler. System dimensions are 18 x 32 ...
... The Cytomics FC 500 ... family equipped with the most ... 500 Series delivers flexible testing, ... interface features that help researchers ...
... Reader is Cellomics‘ latest product ... Cell-based Screening". The KineticScan Reader ... do both temporal and high-resolution ... dynamic distribution and activity of ...
... may be superior to transfection in some ... with PULSin you can study lethal proteins ... of proteins in cells. Likewise, delivery of ... traditional RNA interference experiments. ,With PULSin ...
Biology Products: